Amylin Drug Race Heats Up with $19B in Deals, 40 Programs in Development
Event summary
- PatentVest released a report on March 31, 2026, detailing the $19B amylin drug race transforming obesity treatment.
- Over 40 amylin receptor agonist programs are currently in development worldwide.
- First GLP-1/amylin combination therapy nearing FDA decision.
- Clinical data shows up to 20%+ weight loss with amylin-based therapies.
- Oral small-molecule amylin programs emerging as potential market expanders.
The big picture
The amylin mechanism, once considered commercially unviable, is now central to global pharmaceutical strategy. With $19B in deals and 40 programs in development, the race is on to build the next pillar of obesity medicine. The value proposition is shifting from clinical data to patent strategy, with major players like Novo Nordisk, Eli Lilly, and Roche actively building positions.
What we're watching
- Patent Strategy
- How patent depth will determine long-term competitive advantage in the amylin space.
- Regulatory Decisions
- The impact of upcoming FDA decisions on the first GLP-1/amylin combination therapy.
- Market Expansion
- The pace at which oral small-molecule amylin programs could expand the obesity treatment market.
Related topics